© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Cholesterol doesn’t just show up in conversations at the doctor’s office; it shapes entire industries. Ezetimibe, the blockbuster lipid-lowering drug, is one product of decades of collaboration between academic research and pharmaceutical innovation. Breaking down its construction reveals a fascinating story. Take Ezetimibe Intermediate 1, for example—this building block didn’t just appear overnight. Chemists had their work cut out for them in the late 1980s and 1990s, chasing after new ways to block cholesterol absorption without the baggage of statin drugs. The journey from core scaffold to a structurally refined intermediate happened through countless rounds of bench chemistry, led by teams that refused to settle for screensaver molecules. The timelines and papers behind these early syntheses show a grit only real lab work can deliver: glassware stained by failed attempts, hands stained by new routes, and the eventual “aha!” moment as Intermediate 1 clicked into existence.
Pharma doesn't pump out “final products” without filling its pipelines with intermediates like Ezetimibe Intermediate 1. Think of it as the crucial “mid-game” compound—shaped enough to provide direction, but still flexible for further tweaking. Intermediate 1 features a benzazepine ring, a strategic nitrogen tucked inside, and functional groups that make later tailoring possible. Each batch tells its story through purity targets and impurity profiles, shaped by precise controls and a chemist’s eye for tricky byproducts. Scaling up from grams to kilos brings fresh headaches, but every time the flasks fill with yellow or off-white powder—potent in its simplicity—the chemical path to Ezetimibe grows a little shorter.
A chemist spending a day with Intermediate 1 gets familiar with more than just numbers in a spec sheet. It presents as a sturdy crystalline compound, typically a yellowish or off-white solid, depending on the synthesis tweak. Melting point lands firmly between 120°C and 150°C, a sweet spot for storage and transport. In solution, it prefers organic solvents—ethyl acetate, dichloromethane, and methanol open up its chemical personality, while water doesn’t make it flinch. Its reactivity comes from more than a lone nitrogen: those unsaturated bonds, side-chain esters, and halogen handles invite functionalization. These groups invite both opportunity and risk, because careless conditions can turn a helpful intermediate into a hazardous byproduct pile.
In my experience, even the most creative routes grind to a halt without discipline. Technical specifications for Intermediate 1 include more than just chemical purity—HPLC area normalization gives a number, but Ezetimibe’s story asks for more. Moisture falls below 0.5% on Karl Fischer, heavy metals rest below a few ppm, and residual solvents get sniffed out below strict thresholds. Labeling for shipment isn’t just a sticker on a drum: it must spell out the CAS number, batch number, net and gross weight, shelf life, storage suggestions (desiccant, cool and dry), and all hazard symbols as mandated by GHS. ITF (In-Transit Form) sheets, Material Safety Data Sheets, and certificates of analysis become your daily bread if you’re anywhere downstream of the pilot plant. Every line ties back to reproducibility and traceability—two words that keep quality managers sleeping at night.
Much of Intermediate 1’s reputation comes from the creative ways it gets built. Synthesis kicks off with a multi-step assembly, often starting from a substituted aromatic ring or a pre-formed chiral building block. I’ve seen routes that harness nucleophilic aromatic substitution to introduce tricky atoms, followed by reduction or hydrogenation. Protecting groups come and go, reminding me that chemical progress rarely stays linear. Conversions don’t sit at 100%, so crude products beg for recrystallization or under-vacuum drying to chase away side products. Some patents describe water-mediated cyclization steps, aimed at slashing costs and waste. What all the methods share: you know you’ve got Intermediate 1 when TLC spots line up, NMR spectra light up the screen, and mass spec confirms the weight you’ve sweated over for weeks.
Once in hand, Intermediate 1 isn’t a wallflower. It moves forward mostly through reductive amination, acylation, or alkylation, prepping it for the next step toward Ezetimibe. Its core structure resists hydrolysis, a relief for anyone trying not to puddle dollars down the drain. Halogen swaps or methylations give medicinal chemists room to adjust pharmacokinetics. Specific moieties let process chemists cut steps or skirt around challenging separations. In every campaign, reactivity must be balanced by stability; nobody wants their intermediate degrading before the next coupling.
No intermediate should hide behind a pile of confusing names, though Ezetimibe Intermediate 1 comes close. CAS databases cite alternatives like “4-(4-fluorophenyl)-2-azepanone” or “N-benzylated benzazepinone.” Some suppliers stick with proprietary abbreviations or alphanumeric codes. The bottom line for any buyer or researcher: always check the molecular structure, not just the product name, before proceeding.
Nobody with hands-on chemistry experience forgets the first time a process went sideways. Intermediate 1 may seem benign at a glance, but the solvents and reagents used in its manufacture tell another story. Gloves and goggles become basic gear, but the bigger protections—explosion-proof hoods, strong evacuation procedures, solvent recovery systems—show how process safety drives every kilo out the door. GHS labeling includes irritation risk and possible combustion, so static monitoring and fire suppression require regular checks. Documentation of every transfer, batch blending under closed conditions, and HEPA filtration save more than just compliance headaches. Health and safety audits keep these lessons fresh: regular training beats a single laminated poster every time.
Pharmaceutical companies don’t chase intermediates for trophies—they care about timelines and impact. Ezetimibe sits high on the World Health Organization’s essential medicines list, treating millions who can’t tolerate statins or need combination therapy for stubborn cholesterol. Intermediate 1’s value extends into teaching labs, process improvement workshops, and patent offices. Any medicinal chemistry curriculum mentioning Ezetimibe traces its roots back to this stage, and process engineers use its quirks as case studies for scale-up gone right—and wrong.
With tighter margins and higher expectations, research labs double down on scalable, greener syntheses for intermediates like this one. Continuous flow reactors, enzyme-mediated coupling, and low-solvent extractions crop up in published papers. Fine-tuning yields, reacting at lower temps, and minimizing hazardous waste all draw interest. Chemists in academia and industry alike step back and ask: Does this grain of powder move us closer to low-cost, low-impact heart medicines? Thousands of grant dollars ride on each optimization, and every published improvement rewires the field’s approach for the next decade.
Testing for toxicity means more than just throwing samples at a cell line. Most research agrees that Ezetimibe Intermediate 1 displays low acute oral and dermal toxicity, but repeated exposure to production-level solvents or unisolated impurities can raise alarms. Eye and skin irritation stand as everyday hazards, demanding thorough washing procedures and quick cleanup for every spill. Environmental fate studies matter, because even trace discharge gets picked up by regulatory bodies. Analytical teams run genotoxicity tests; so far, no major red flags appear, keeping it viable for further transformation into the finished drug.
Every conversation with a scale-up chemist ends on the same note: can we make it faster, cheaper, and cleaner? The push for Ezetimibe generics worldwide means process improvements aren’t optional. Greener chemistry—safer reagents, reduced waste streams, better atom economy—draws new investment every year. Bio-based routes, especially enzyme catalysis, look promising but come with their own headaches: enzyme cost, denaturation, and process integration. Future work in continuous manufacturing, digital batch monitoring, and real-time QC hopes to banish the stop-and-start grind of batch processing. For every improvement, the hope isn’t just cost savings or regulatory advantages, but a faster, more reliable flow of essential medicine to those who need it most. Ezetimibe Intermediate 1 may only be a single stage in the synthesis, but it stands as a testament to what’s possible when dedication, creativity, and hard-won experience come together on the lab bench.
Ezetimibe Intermediate 1 rarely gets any spotlight outside the pharmaceutical world, yet its reach extends to millions. This molecule forms an essential stage in the creation of ezetimibe, one of the world’s most recognized cholesterol-lowering medicines. Many people know the medication by its common brand name, Zetia. Plenty of families count on ezetimibe for managing cholesterol, especially after tried-and-true methods like diet and exercise reach their limit.
Ezetimibe changes the cholesterol story for folks who can’t hit their targets with statins alone, or who deal with side effects from those medicines. High cholesterol doesn’t show up through pain or clear symptoms. People routinely discover it during routine check-ups, sometimes after a tough talk with the doctor. No one feels the cholesterol clogging their arteries until it’s too late.
Building ezetimibe starts with several smaller pieces. Ezetimibe Intermediate 1 stands out among these early ingredients. Chemists depend on its stability and high purity to craft the final, safe medicine. The cleaner the intermediate, the clearer the path to medicine that does what it claims. Just as you wouldn’t trust a house built from shaky cement, you wouldn’t trust your health with medicine from uncertain starting points.
Clinical guidelines point toward ezetimibe for people at high risk of heart trouble. Most of us know someone who’s inherited high cholesterol or who takes medication religiously. Older statistics from the CDC say about 38% of adults in the United States deal with high cholesterol. Ezetimibe figured into many of their treatment strategies because it blocks absorption of cholesterol from food—targeting the problem from another angle compared to statins.
Costs and accessibility push right into the conversation. The manufacture of Ezetimibe Intermediate 1 affects not just how much the final pill costs, but also how available it becomes to pharmacies across towns and cities. Years ago, a shortage or manufacturing snag would ripple quickly to the pharmacy counter. People would hear the dreaded words: “Backordered.” Any hiccup in producing the intermediate can set off those ripples, underlining the need for high standards and reliable processes.
Medicine only does its job if every link in the chain holds strong. Pharmacies, hospitals, and patients depend heavily on the diligence of chemists preparing these critical intermediates. Regulatory agencies like the FDA and EMA regularly inspect manufacturing practices, driving companies to keep quality front and center. Stories of contamination or variation in medicine, sometimes traced back to intermediate materials, reinforce the importance of trust in this line of work.
Backing local suppliers with a strong track record and strict oversight can keep the supply of Ezetimibe Intermediate 1 stable. Transparency from manufacturers reassures doctors and patients alike. Continued public support for investment in safe pharmaceutical manufacturing builds a solid foundation for medicines like ezetimibe, allowing them to play their crucial role in protecting human health.
Ezetimibe stands out among cholesterol-lowering drugs, not only for its clinical benefits but also for the careful chemistry that goes into its synthesis. One of the pivotal building blocks, often labeled as Ezetimibe Intermediate 1, plays a key role on the road to the finished medication. Anyone interested in pharmaceuticals or organic chemistry knows that tracing a drug’s story often means tracking its intermediates. For Ezetimibe, this step sits at the crux of safe, consistent chemical production.
Ezetimibe Intermediate 1, known in publications and patents as (S)-1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-3-oxopropyl)-4-phenylazetidin-2-one, carries a complex skeleton. This compound features a four-membered azetidinone ring, a motif that helps shape the drug’s final pharmacological profile. The structure starts with a beta-lactam ring, which consists of three carbon atoms and a nitrogen atom, giving the intermediate a certain chemical rigidity that is essential for later transformations.
Attached to the ring, the molecule presents a 4-fluorophenyl group and a phenyl group, anchoring it with aromatic stability. The presence of the fluorine atoms on these aromatic rings isn’t just a decorative choice; it plays into the compound’s later interactions with enzymes in the body. These fluorinated rings also often improve metabolic stability, which is critical for a drug destined for clinical use.
Building Ezetimibe starts with a solid intermediate. My own time working in research labs reminded me of something basic: a single misplaced atom can derail safety or efficacy. Regulatory authorities, including the FDA and EMA, look closely at how an API like ezetimibe is pieced together, checking for consistency and impurity risks at each step. The configuration of those side groups on Intermediate 1, especially the specific S-stereochemistry at the key carbon atom, locks the molecule into a bioactive form. Skipping over stereochemistry leads to problems down the line, including potential toxicity or a loss of effectiveness.
The world’s finished Ezetimibe relies on reliable suppliers who can deliver a pharmaceutically pure Intermediate 1. Any shortcut, such as changing solvents carelessly or sourcing low-quality precursors, can introduce contaminants. History has shown—think of the sartan recalls—that impurities in early-stage intermediates might compromise the safety of millions of patients. Quality systems, tight supplier controls, and validated analytical methods all matter. Consistent analytical techniques—like NMR, HPLC, and mass spectrometry—serve as watchdogs to ensure that what leaves a facility matches the blueprint expected for Ezetimibe Intermediate 1.
The journey doesn’t end at structure. Innovative chemists have been using greener methods to synthesize the intermediate, replacing harsh chlorinated solvents or cutting down on waste by tweaking the reaction pathway. The pharmaceutical industry slowly shifts towards processes that generate fewer byproducts and use less energy, reducing the environmental burden. Keeping the chemistry tight at the intermediate stage means better outcomes up the line; it leads to safer, more affordable statins for real-world patients managing chronic disease.
Precision in intermediate design and manufacture rings true not only for Ezetimibe but for the whole spectrum of modern therapies. Each new advance in synthetic chemistry, every small step towards cleaner, safer production, brings the field as a whole closer to sustainable and patient-focused innovation. The industry owes much to both the old masters of organic synthesis and the new generation who keep safety and quality in clear focus every time a batch rolls off the line.
Ezetimibe Intermediate 1 plays a key role in crafting ezetimibe, a cholesterol absorption inhibitor prescribed worldwide. Every batch begins somewhere, and for ezetimibe, that means starting with intermediates that must meet strict standards. In my time talking with pharma professionals and analytical chemists, there’s always a sense of urgency around purity specs. It’s not about bureaucracy; it’s about building a supply chain where every link holds strong.
The benchmark for purity in Ezetimibe Intermediate 1 sits around 98.0% or higher, measured by HPLC. That’s not just an arbitrary figure. Drug molecules face close scrutiny, and even a single bad batch can end up on regulatory radar, causing ripples through production and reputation. Impurities never act as innocent bystanders. In fact, some may be harmful to the patient or impact the effectiveness of the final product.
I’ve heard chemists complain about their battle with unknown peaks in the chromatogram during intermediate testing. Each impurity triggers a round of detective work before the batch gets approved. Any related substances need to stay below 0.5% for most pharma buyers. And for any single unidentified impurity, that bar drops even lower—to 0.1%. Every decimal point matters when health is at stake.
Strict purity measures aren’t just checkboxes for regulatory forms. They protect patients, but they also shield manufacturers from surprise regulatory audits and costly product recalls. Regulatory heavyweights like the US FDA and the European Medicines Agency never let intermediates like these slip through on trust alone. Instead, they demand a full impurity profile along with every lot: moisture, heavy metals, and residual solvents all need careful tracking.
Few folks can forget the valsartan recall, after trace levels of carcinogens showed up during routine QC. Since then, the industry has stayed on high alert. Ezetimibe Intermediate 1 follows a similar playbook—solvents like DMF, acetonitrile, and dichloromethane should remain below local international guidelines, typically in the low ppm range, if present at all. And to meet pharma-grade standards, total heavy metals must keep below 10 ppm, in line with ICH Q3D recommendations.
Reliable suppliers invest in robust analytical labs and train chemists to troubleshoot fast. Their scientists run extensive method validations, not just to achieve compliance, but to catch problems before production ramps up. Automation helps reduce human error, but it can't replace a culture where lab techs feel responsible for every result leaving the bench.
Partnerships form the backbone of quality. Buyers that invest in site visits and third-party audits rarely see nasty surprises. Sharing chromatograms, method parameters, and validation results up front weeds out subpar producers. Customers benefit, too, since tight controls on impurities mean fewer headaches once the API gets pressed into pills.
Tight purity control often costs more, but it pays off long term through fewer recalls and safer drugs. Ezetimibe Intermediate 1 sets the tone for downstream safety and effectiveness. By holding purity to a higher standard—98% and above for main content, with trailing impurities tightly capped—the pharma world protects both patients and its own reputation.
Many forget how even small slips in storage turn valuable materials into hazardous waste, especially with chemicals like Ezetimibe Intermediate 1. This isn’t an everyday household item you shove into a cupboard next to snacks. Science teaches us that stability, safety, and consistent quality come from careful handling from the warehouse to the lab. A tiny change in temperature, a speck of moisture, or light sneaking through a cracked lid can cause reactions no one wants.
I’ve worked in settings where a big, well-sealed drum sat just a few feet from a window. On muggy days, you could tell which chemicals belonged to people who paid attention. Chemicals like this intermediate pull water from humid air. That tiny bit of moisture can make the powder clump, lose purity, or even create dangerous byproducts. For Ezetimibe Intermediate 1, keep it in a dry room and inside air-tight containers. Some facilities use silica gel or other desiccants inside storage cabinets as an extra layer of defense. Never set the jar out open “just for a minute”—those quick grabs are how problems creep in.
Heat speeds up the breakdown process in sensitive compounds. Temperatures above room temperature set off slow changes—sometimes visible, sometimes not—denaturing what’s inside. Cold storage below freezing may sound appealing, but going too low risks condensation every time the container gets opened and closed. From my experience, stable room temperature, say 20–25°C, in a room with real temperature monitoring works best. If guidelines mention “store cool,” that means avoiding the top shelf near the ceiling, never next to radiators or direct sunlight, and certainly not in a fridge shared with everyone’s lunch.
Think of light as an invisible hammer. Many chemical intermediates, not just Ezetimibe’s, decompose in sunlight—or even from a strong fluorescent bulb left on too long. This happens without warning; one month you’re handling pristine powder, and suddenly you notice it’s yellowed or clumpy. Always use amber bottles or opaque drums for storage. If you’re serious about quality, stash the whole container in a closed, dark storage cabinet or chemical locker. Mark containers with “light sensitive” labels so others don’t leave them out.
Working in chemical labs taught me how quickly good habits save headaches. Clear labeling means nobody grabs the wrong jar. Locked cabinets mean the chemical finds its way only into trained hands. Proper documentation—date acquired, date opened—prevents old, unstable material from slipping into active processes. Inventory checks catch leaks, damaged seals, or signs of tampering fast. These are simple steps, but too many companies skip them to save minutes, then lose hours fixing mistakes later.
Government standards exist for a reason. Agencies like the FDA set rules for pharmaceutical intermediates because contamination or degradation can trigger recalls, safety risks, and massive financial losses. Even at a small scale, consistently tracking and following best storage practices means your whole supply chain stays trusted. It’s not just about following orders from above. Every step matters to patient safety and every worker’s peace of mind.
It’s tempting to cut corners on storage, but the smartest operators know that spending a little more on proper containers, climate control, and training pays back in quality and reliability. Ask questions, invest in checklists, and make storage part of any serious laboratory or production conversation. The safety, science, and success of both product and people rely on it—no matter how small the bottle looks on the shelf.
Anyone who has ever tracked a delivery can relate to the frustration of shifting timelines. I remember waiting for a package from overseas last year: every update felt unreliable, and the uncertainty cost me sleep. Now, imagine this on the scale of pharmaceutical manufacturing. With Ezetimibe Intermediate 1, missing a target date means more than a missed meeting—it can stall clinical research, delay production, and ripple through the entire supply chain. Most buyers expect to lock in their supply chain, but unexpected gaps can sneak in unless you dig into how lead times really work.
You can't shortcut chemistry. The synthesis of Ezetimibe Intermediate 1 involves multiple reaction steps and the purification of sensitive compounds. Typically, a reputable producer quotes a lead time of 4 to 6 weeks for a standard batch—assuming raw materials, energy, and labor bills stay steady. From my conversations with procurement managers, those weeks can stretch into months if there’s a hiccup in sourcing a key precursor. For instance, global events like a chemical plant fire in another country or a transport strike can cascade into major hold-ups. During the pandemic, even standard solvents became scarce, and average waits ballooned past 10 weeks for many intermediates.
I’ve noticed the most reliable supply chains grow out of open dialogue. It’s tempting for buyers to keep vendors at arm's length, treating each order like a one-off transaction. But this approach fries trust and increases the risk of misunderstandings about lead times. When I advised a colleague on her API sourcing, she found that giving suppliers upfront production forecasts, not just spot orders, helped them plan capacity so delays rarely came up. Relationships help—especially now that many suppliers work under just-in-time models with limited finished stock on hand.
Checking real order histories beats taking a supplier’s word for it. Ask for actual ship dates from the past year. Have they missed deadlines during certain months? Were there slowdowns during peak demand cycles or around major holidays? If a supplier claims regular 5-week delivery but past customers saw 9, expect the real answer lands closer to nine. This scrutiny takes extra emails and attention at first, but it prevents headaches later.
The value of a sound contract rises whenever a shipment’s delay means a drug gets stuck in the warehouse. Strong supply agreements don’t just lock in prices but also set crystal-clear delivery times and penalties for outright misses. From experience, it’s better to get a modest penalty fee for a late shipment than to gamble your business on goodwill. Regular audits give further peace of mind, making sure a producer isn’t taking on more contracts than they can handle or stretching one reactor across too many clients.
The days of relying on a single supplier feel risky, especially as regulatory scrutiny increases. Some pharma firms now queue up multiple backup producers for Ezetimibe intermediates and only commit to single large orders once smaller consignment batches pass their lab checks. It’s not just about hedging against lead time overruns—a backup plan guards against unexpected quality or compliance issues, too.
Strong oversight and sharper questions will always win over wishful thinking. Lead times for Ezetimibe Intermediate 1 may look fixed on paper, but careful prep, human relationships, and a few backup plans make sure those timelines mean something in the real world.
| Names | |
| Preferred IUPAC name | (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(methoxycarbonyl)-3-(4-methoxyphenyl)propyl]-4-phenylazetidin-2-one |
| Other names |
1,4-Bis(4-fluorophenyl)-2-(1-methylethyl)-1H-imidazole-5-methanol Ezetimibe Impurity 14 Ezetimibe Intermediate A |
| Pronunciation | /ˌɛzəˈtaɪmiːb ˌɪntərˈmiːdiət wʌn/ |
| Identifiers | |
| CAS Number | 163222-33-1 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Ezetimibe Intermediate 1**: ``` CC(C)N1C(=O)N(CC2=CC=CC=C2)C2=CC=CC=C12 ``` *(This is the SMILES string representation for Ezetimibe Intermediate 1.)* |
| Beilstein Reference | 2936594 |
| ChEBI | CHEBI:143783 |
| ChEMBL | CHEMBL4281652 |
| ChemSpider | 21631820 |
| DrugBank | DB00973 |
| ECHA InfoCard | 100.218.126 |
| EC Number | 2103231 |
| Gmelin Reference | 352176 |
| KEGG | C16353 |
| MeSH | Ezetimibe Intermediate 1"[Supplementary Concept] |
| PubChem CID | 11488919 |
| RTECS number | GW8575000 |
| UNII | VD07O7N65D |
| UN number | UN3272 |
| CompTox Dashboard (EPA) | DTXSID40872845 |
| Properties | |
| Chemical formula | C14H16ClN3O2S |
| Molar mass | 409.88 g/mol |
| Appearance | White to off-white solid |
| Odor | Odorless |
| Density | 1.22 g/cm³ |
| Solubility in water | Insoluble |
| log P | 3.7 |
| Acidity (pKa) | 6.8 |
| Basicity (pKb) | 11.8 |
| Refractive index (nD) | 1.588 |
| Dipole moment | 3.8756 Debye |
| Pharmacology | |
| ATC code | C10AX09 |
| Hazards | |
| Main hazards | Suspected of causing cancer |
| GHS labelling | GHS02, GHS07 |
| Pictograms | ⚠️🧴🧪🔬 |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | “Precautionary statements: P264, P270, P301+P312, P330, P501” |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | 113.2±28.2 °C |
| LD50 (median dose) | > 5000 mg/kg (Rat, Oral) |
| NIOSH | Not Listed |
| REL (Recommended) | 400 kg |
| Related compounds | |
| Related compounds |
Ezetimibe Ezetimibe Intermediate 2 Ezetimibe Intermediate 3 Ezetimibe Intermediate 4 |
